期刊
CANCER GENE THERAPY
卷 21, 期 9, 页码 389-396出版社
SPRINGERNATURE
DOI: 10.1038/cgt.2014.43
关键词
-
类别
资金
- National Science Council, Taiwan [NSC 98-2320-B-010-003-MY3, NSC 101-2320-B-010-071-MY3]
- Taipei Veterans General Hospital, Taiwan [V96ER2-013, V96B2-019, V98C1-165]
- Taiwan Clinical Oncology Research Foundation
Thymosin beta-4 (T beta(4)) is known to be involved in tumorigenesis. Overexpression of this polypeptide has been observed in a wide variety of cancers, including colorectal carcinoma (CRC). Accordingly, T beta(4) has been proposed to be a novel therapeutic target for CRC, especially in its metastatic form. Although in vitro tumor-suppressive effects of T beta(4) gene silencing mediated by small hairpin RNA (shRNA) have already been demonstrated, the in vivo efficacy of such an approach has not yet been reported. Herein, we demonstrated that infection with recombinant adenovirus expressing an shRNA targeting T beta(4) markedly reduced the growth of and robustly induced apoptosis in CT-26 mouse CRC cells in culture. Additionally, tumors grown in nude mice from the CT-26 cells whose T beta(4) expression already been downregulated by virus infection were also drastically reduced. Most importantly, significant growth arrest of tumors derived from the parental CT-26 cells was observed after multiple intratumoral injections of these viruses. Together, our results show for the first time that in vivo silencing of T beta(4) expression by its shRNA generated after adenoviral infection can suppress CRC growth. These results further demonstrate the feasibility of treating CRC by a T beta(4) knockdown gene therapeutic approach.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据